Kolexia
Moro-Sibilot Denis Pneumologie
Moro-Sibilot Denis
Pneumologie
Hôpital Nord Grenoble
La Tronche, France
1.1 K Activités
2 K Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du poumon Carcinome pulmonaire non à petites cellules Carcinome pulmonaire à petites cellules Adénocarcinome Métastase tumorale Adénocarcinome pulmonaire Carcinomes Mésothéliome Mésothéliome malin

Collaborateurs

Voir plus
Barlesi Fabrice
Barlesi Fabrice
Gustave-Roussy, Villejuif, France
Girard Nicolas
Girard Nicolas
Clcc Institut Curie, Paris, France
Mazieres Julien
Mazieres Julien
Hôpital Rangueil, Toulouse, France
Audigier-Valette Clarisse
Audigier-Valette Clarisse
Centre Hospitalier Toulon, Toulon, France

Industries

Voir plus
MSD
34 collaboration(s)
Dernière en 2023
BMS
31 collaboration(s)
Dernière en 2023
Edimark
28 collaboration(s)
Dernière en 2023
Roche
23 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
RELAY: A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination With Ramucirumab or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer
Essai Clinique (Lilly)   15 mars 2024
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3): Randomized, Open-label, Multicenter, Phase 3 Trial of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
Essai Clinique (BMS)   11 mars 2024
ORAKLE: A Phase II Non-randomized, Single Group Assignment, Open-label, Multicenter Study of Efficacy and Safety of Lorlatinib Monotherapy After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer
Essai Clinique (Intergroupe Francophone de Cancérologie Thoracique)   06 mars 2024
Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK): A Phase II Randomized, Open-Labelled, Multicenter Study of Safety & Efficacy of Combination Brigatinib and Carboplatin-Pemetrexed Therapy or Brigatinib Monotherapy as First-Line Treatment in Advanced ALK-Positive Non-Small Cell Lung Cancer
Essai Clinique (Intergroupe Francophone de Cancérologie Thoracique)   06 mars 2024
MELROSE: Phase 2 Study Evaluating MEchanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtinib Until and Beyond Radiological Progression : the MELROSE Trial
Essai Clinique (AstraZeneca)   26 février 2024
AcSé CRIZOTINIB : Secured Access to Crizotinib for Patients With Tumors Harboring a Genomic Alteration on One of the Biological Targets of the Drug.
Essai Clinique (Unicancer)   26 février 2024
Lung cancer, comorbidities, and medication: the infernal trio.
Frontiers in pharmacology   21 février 2024
TRIDENT-1: A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
Essai Clinique (Turning Point Therapeutics, Inc.)   05 février 2024
Argonaut: A Phase 1 Study of the SHP2 Inhibitor BBP-398 (Formerly Known as IACS-15509) in Combination With the KRAS-G12C Inhibitor Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation
Essai Clinique (Navire Pharma Inc., a BridgeBio company)   31 janvier 2024
LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer: A Phase III Multicenter, Randomized Study of Oral LDK378 Versus Standard Chemotherapy in Previously Untreated Adult Patients With ALK Rearranged (ALK-positive), Stage IIIB or IV, Non-squamous Non-small Cell Lung Cancer
Essai Clinique (Novartis)   22 janvier 2024